Blueprint Medicines announces approval of AYVAKYT for treatment of ISM patients in Europe

Blueprint Medicines Corporation today announced the European Commission has approved AYVAKYT® (avapritinib) for the treatment of adult patients with indolent systemic mastocytosis (ISM) with moderate to severe symptoms inadequately controlled on symptomatic treatment. AYVAKYT is the first and only approved therapy for people living with ISM in Europe.

Identifying a signature biomarker for early-onset Alzheimer’s disease

Alexandra Touroutoglou, PhD, and Bradford Dickerson, MD, neuroscientists in the department of Neurology at Massachusetts General Hospital, are the lead authors of a new study

October 19, 2023

aap informs about the invitation to the Annual General Meeting on January 15, 2025 – Biotech Investments

EQS-News: aap Implantate AG / Key word(s): AGM/EGM aap informs about the invitation to the Annual General Meeting on January 15, 2025 09.12.2024 / 07:30

December 10, 2024

Bipartisan House group calls on FDA to ensure OTC and prescription versions of a drug cannot be marketed simultaneously

Reps. Debbie Dingell (D-MI), Robert Latta (R-OH) and Dan Crenshaw (R-TX) sent a letter yesterday to Patrizia Cavazzoni, the head of FDA’s Center for Drug

September 8, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.